The FDA perspective on the development of stereoisomers.

The current regulatory position of the Food and Drug Administration is discussed with regard to the approval of racemates and pure stereoisomers. Circumstances in which stereochemically sensitive analytical methods are necessay to ensure the safety and efficacy of a drug are described. Regulatory guidelines are interpreted for applications for the approval of a pure enantiomer in which the racemate is marketed, for the approval of eitehr a racemate or a pure enantiomer in which neither is marketed, and for clinical investigations to compare the safety and efficacy of a racemate and its enantiomers. Examples of te basis for such regulation are drawn from historical situations (thalidomide, benoxaprofen) as well as currently marketed drugs (arylproionic acids, disopyramide, indacrinone).

[1]  N. Singh,et al.  Pharmacokinetics of the enantiomers of tiaprofenic acid in humans. , 1986, Journal of pharmaceutical sciences.

[2]  M. Simonyi.  On chiral drug action , 1984, Medicinal research reviews.

[3]  J. Caldwell,et al.  The metabolic chiral inversion of 2−arylpropionic acids–‐A novel route with pharmacological consequences–‐a correction , 1985, The Journal of pharmacy and pharmacology.

[4]  E. J. Ariëns,et al.  Bias in pharmacokinetics and clinical pharmacology , 1987, Clinical pharmacology and therapeutics.

[5]  D. Drayer.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview , 1986, Clinical pharmacology and therapeutics.

[6]  G. Blaschke,et al.  Chromatographische Racemattrennungen, X. Racemattrennung des Thalidomids und anderer Glutarimid‐Derivate , 1980 .

[7]  J. Finney,et al.  Random Close Packing and the Heats of Fusion of Argon at High Pressures , 1967, Nature.

[8]  Vladimir Prelog,et al.  Specification of Molecular Chirality , 1966 .

[9]  E. Ariëns.  Stereochemistry: A source of problems in medicinal chemistry , 1986, Medicinal research reviews.

[10]  J. Caldwell,et al.  The Importance of Stereochemistry in the Clinical Pharmacokinetics of the 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs , 1984, Clinical pharmacokinetics.

[11]  S. Fabro,et al.  Toxicity and Teratogenicity of Optical Isomers of Thalidomide , 1967, Nature.

[12]  J. Montgomery,et al.  Synthesis of D- and L-thalidomide and related studies. , 1968, Journal of pharmaceutical sciences.

[13]  V. Cirillo,et al.  Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio , 1981, Clinical pharmacology and therapeutics.

[14]  E. R. Shepard,et al.  Stereoselective inversion of (R)-(-)-benoxaprofen to the (S)-(+)-enantiomer in humans. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Caldwell,et al.  The metabolic chiral inversion of 2‐arylpropionic acids—a novel route with pharmacological consequences , 1983, The Journal of pharmacy and pharmacology.

[16]  K. Hellmann,et al.  Effect of Thalidomide on the Graft versus Host Reaction , 1966, Nature.